Mir195 enables Ebf1-deficient hematopoietic progenitor cells to mature into B cells, suggesting some miRNA can substitute for transcription factors in differentiation.

In a milestone for the hematologic oncology landscape, the first patient has been dosed in a phase 1/2 clinical trial (NCT07220616) evaluating DS3790, a potential first-in-class antibody-drug ...

B cell development in swine presents a unique model within mammalian immunology. In contrast to traditional murine and human systems, swine exhibit notable differences in the temporal order of heavy ...

Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.

In this interview, industry experts Mathieu Bennet and Dustin Whitson explore how automation and single-cell technologies are transforming high-throughput B-cell cloning for antibody discovery. Can ...

New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B ...

Sonrotoclax is a next-generation and potentially best-in-class investigational B-cell lymphoma 2 (BCL2) inhibitor with a unique pharmacokinetic and pharmacodynamic profile. Studies in the lab and ...

A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the progression of type 1 diabetes (T1D).

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

The development of humans and other animals unfolds gradually over time, with cells taking on specific roles and functions ...